Janaina R. Xavier

Rio De Janeiro, RJ 21040360, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Correction: Denani et al. Pseudovirus-Based Neutralization Assays as Customizable and Scalable Tools for Serological Surveillance and Immune Profiling. Pathogens 2025, 14, 1129.

Correction: Denani et al. Pseudovirus-Based Neutralization Assays as Customizable and Scalable Tools for Serological Surveillance and Immune Profiling. Pathogens 2025, 14, 1129.

Journal: Pathogens (Basel, Switzerland)

Published: January 27, 2026

A cohort study of the duration of immunity to yellow fever after 4 years of primary vaccination in children and adults.

A cohort study of the duration of immunity to yellow fever after 4 years of primary vaccination in children and adults.

Journal: Transactions of the Royal Society of Tropical Medicine and Hygiene

Published: November 27, 2025

Pseudovirus-Based Neutralization Assays as Customizable and Scalable Tools for Serological Surveillance and Immune Profiling.

Pseudovirus-Based Neutralization Assays as Customizable and Scalable Tools for Serological Surveillance and Immune Profiling.

Journal: Pathogens (Basel, Switzerland)

Published: October 07, 2025

Risk factors for post-COVID-19 condition: A case-control study in municipalities of Paraíba and Rio de Janeiro, Brazil.

Risk factors for post-COVID-19 condition: A case-control study in municipalities of Paraíba and Rio de Janeiro, Brazil.

Journal: The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

Published: October 06, 2025

Immunogenicity of a single dose of the 17DD yellow fever vaccine in a cohort of adults and children in a non-endemic area, and its association with dengue and Zika seropositivity.

Immunogenicity of a single dose of the 17DD yellow fever vaccine in a cohort of adults and children in a non-endemic area, and its association with dengue and Zika seropositivity.

Journal: PLoS neglected tropical diseases

Published: May 17, 2024

Homologous equivalence study of immunogenicity after third dose of Covid-19 vaccine (recombinant) with an interval of six months after the second dose, comparing the interval of eight and 12 weeks between the first two doses.

Homologous equivalence study of immunogenicity after third dose of Covid-19 vaccine (recombinant) with an interval of six months after the second dose, comparing the interval of eight and 12 weeks between the first two doses.

Journal: Memorias do Instituto Oswaldo Cruz

Published: April 25, 2024

Duration of post-vaccination immunity to yellow fever in volunteers ten years after a dose-response study - A complementary study.

Duration of post-vaccination immunity to yellow fever in volunteers ten years after a dose-response study - A complementary study.

Journal: Vaccine

Published: April 15, 2024

Vaccine-induced immune thrombotic thrombocytopenia post COVID-19 booster vaccination in Brazil: a case series.

Vaccine-induced immune thrombotic thrombocytopenia post COVID-19 booster vaccination in Brazil: a case series.

Journal: Research and practice in thrombosis and haemostasis

Published: May 10, 2023

Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha.

Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha.

Journal: Frontiers in cellular and infection microbiology

Published: January 20, 2021

Corrigendum: Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.

Corrigendum: Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.

Journal: Frontiers in immunology

Published: September 09, 2019

Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.

Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.

Journal: Frontiers in immunology

Published: March 19, 2019

Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study.

Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study.

Journal: Vaccine

Published: March 13, 2018

Showing 1-12 of 13

Last Updated: 09/26/2026